Hepion Pharmaceuticals Inc. [NASDAQ: HEPA] gained 9.04% on the last trading session, reaching $1.81 price per share at the time. The company report on December 10, 2020 that Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a ‘AMBITION’ Clinical Trial for NASH.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)(“Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, announced that, in addition to completing patient dosing in the 75 mg CRV431 cohort of its Phase 2a ‘AMBITION’ clinical trial, it has dosed the first NASH patient in the 225 mg CRV431 dosing cohort.
The open-label Phase 2a ‘AMBITION’ study is designed to assess safety, tolerability, pharmacokinetics and biomarker analyses for early assessments of efficacy of 75 mg and 225 mg CRV431, administered orally to F2 and F3 NASH patients (n=18/dosing group), once daily for 28 days. Hepion will also conduct Fibroscans and examine a multitude of candidate biomarkers of NASH resolution and CRV431 efficacy including Pro-C3, Enhanced Liver Fibrosis (ELF) markers, collagens, matrix metalloproteinases, transcriptomics, liver transaminases, and full-scale lipidomic and genomic signatures. Identification of biomarkers will be facilitated by Hepion’s proprietary, machine-learning platform, AI-POWR™.
Hepion Pharmaceuticals Inc. represents 9.03 million in outstanding shares, while the company has a total market value of $57.25 million with the latest information. HEPA stock price has been found in the range of $1.58 to $1.91.
If compared to the average trading volume of 863.18K shares, HEPA reached a trading volume of 9398756 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Hepion Pharmaceuticals Inc. [HEPA]:
ROTH Capital have made an estimate for Hepion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 20, 2020.
The Average True Range (ATR) for Hepion Pharmaceuticals Inc. is set at 0.19 The Price to Book ratio for the last quarter was 1.46, with the Price to Cash per share for the same quarter was set at 0.43.
Trading performance analysis for HEPA stock
Hepion Pharmaceuticals Inc. [HEPA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.56. With this latest performance, HEPA shares dropped by -38.85% in over the last four-week period, additionally sinking by -13.81% over the last 6 months – not to mention a drop of -65.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HEPA stock in for the last two-week period is set at 36.25, with the RSI for the last a single of trading hit 41.12, and the three-weeks RSI is set at 36.46 for Hepion Pharmaceuticals Inc. [HEPA]. The present Moving Average for the last 50 days of trading for this stock 2.7449, while it was recorded at 1.6820 for the last single week of trading, and 2.6761 for the last 200 days.
Hepion Pharmaceuticals Inc. [HEPA]: A deeper dive into fundamental analysis
Return on Total Capital for HEPA is now -76.15, given the latest momentum, and Return on Invested Capital for the company is -71.85. Return on Equity for this stock declined to -73.99, with Return on Assets sitting at -46.95. When it comes to the capital structure of this company, Hepion Pharmaceuticals Inc. [HEPA] has a Total Debt to Total Equity ratio set at 4.99. Additionally, HEPA Total Debt to Total Capital is recorded at 4.75, with Total Debt to Total Assets ending up at 3.95. Long-Term Debt to Equity for the company is recorded at 3.74, with the Long-Term Debt to Total Capital now at 3.18.
Reflecting on the efficiency of the workforce at the company, Hepion Pharmaceuticals Inc. [HEPA] managed to generate an average of -$559,891 per employee.Hepion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.60 and a Current Ratio set at 3.60.
Hepion Pharmaceuticals Inc. [HEPA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Hepion Pharmaceuticals Inc. posted -0.53/share EPS, while the average EPS was predicted by analysts to be reported at -0.96/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 44.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HEPA.
An analysis of insider ownership at Hepion Pharmaceuticals Inc. [HEPA]
There are presently around $0 million, or 1.40% of HEPA stock, in the hands of institutional investors. The top three institutional holders of HEPA stocks are: BLACKROCK INC. with ownership of 60,722, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; SABBY MANAGEMENT, LLC, holding 57,309 shares of the stock with an approximate value of $0.1 million in HEPA stocks shares; and BANK OF AMERICA CORP /DE/, currently with $60000.0 in HEPA stock with ownership of nearly 664200% of the company’s market capitalization.
Positions in Hepion Pharmaceuticals Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 12 institutional holders increased their position in Hepion Pharmaceuticals Inc. [NASDAQ:HEPA] by around 193,336 shares. Additionally, 8 investors decreased positions by around 98,558 shares, while 7 investors held positions by with 23,833 shares. The mentioned changes placed institutional holdings at 268,061 shares, according to the latest SEC report filing. HEPA stock had 8 new institutional investments in for a total of 155,934 shares, while 6 institutional investors sold positions of 98,522 shares during the same period.